Skip to main content
RNA logo

RNA · Atrium Therapeutics, Inc. · Executive Compensation

Track RNA — free
$8.39 +0.13 (+1.55%)
Market Cap
$141.29M
Shares
17.11M
Volume · Oct 9 61.78K Avg daily vol (3M) 259.18K

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

No Compensation Data

No Summary Compensation Table has been imported from this company's proxy statements yet.

Executive changes

Person Change Filed
Brendan Winslow Appointed 2026-02-27
Simona Skerjanec Appointed 2026-02-27
Troy Wilson Appointed 2026-02-27
W. Michael Flanagan Appointed 2026-02-27
Carsten Boess Appointed 2026-02-27
Key facts CIK 2093101 CUSIP 04965N104 13F (30d) 6 filings 6 filers Visit website Investor relations